Balyodh Singh Bhangu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Balyodh Singh Bhangu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Adebowale Sylvester Adeyemi
Department of Pharmaceutical Care & Health Systems (PCHS), College of Pharmacy, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA
2 shared publications - Hae Lim
Cardiac Ablation Solutions (CAS), Medtronic, 8200 Coral Sea Street NE, Mounds View, MN 55112, USA
2 shared publications - Harjot Singh Dhaliwal
Department of Clinical & Social Pharmaceutical Sciences, College of Pharmacy, Touro University, 1310 Club Dr., Vallejo, CA 94592, USA
2 shared publications - Olajumoke Aderonmu
Department of Public Health, Western Illinois University, 1 University Circle Road, Macomb, IL 61455, USA
2 shared publications - Omolayo Tinuke Umaru
Department of Pharmaceutical Care & Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, USA
2 shared publications - Taiwo Opeyemi Aremu
Department of Clinical and Social Pharmaceutical Sciences, College of Pharmacy, Touro University California, 1310 Club Dr., Vallejo, CA 94592, USA
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
Global Pharmaceutical Regulation: Comparative Frameworks and Operations
Pharmaceutical regulation plays a central role in protecting public health by governing clinical trials, market authorization, and post-marketing safety monitoring throughout the medicine life cycle. While substantial literature describes established systems, particularly the United States Food and Drug Administration (FDA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and the European medicines regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analyses that integrate both mature authorities, emerging regulators and transnational harmonization networks remain limited. This narrative review draws on primary regulator/network documentation and targeted peer-reviewed literature to compare core regulatory functions across jurisdictions, including approval pathways and evidentiary expectations, inspection and good manufacturing practice (GMP) oversight, transparency practices, and pharmacovigilance and risk-management approaches. Across regions, we observe increasing convergence in scientific expectations through initiatives such as the International Council for Harmonisation (ICH) and reliance and work-sharing models, alongside persistent differences in legal mandates, resourcing, timelines, and data requirements. These differences are most consequential for complex products (e.g., advanced therapies) and in crisis settings, where emergency or conditional authorizations amplify the need for strong lifecycle monitoring, real-world evidence governance, and cross-border communication. We conclude by outlining opportunities to strengthen regulatory resilience and equity through fit-for-purpose harmonization, investment in enabling infrastructure, and future work on interoperable data systems, signal detection, and coordinated post-marketing evaluation.
Top Cited PapersOpen AccessGlobal Pharmaceutical Regulation: Comparative Frameworks and Operations
Pharmaceutical regulation plays a central role in protecting public health by governing clinical trials, market authorization, and post-marketing safety monitoring throughout the medicine life cycle. While substantial literature describes established systems, particularly the United States Food and Drug Administration (FDA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and the European medicines regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analyses that integrate both mature authorities, emerging regulators and transnational harmonization networks remain limited. This narrative review draws on primary regulator/network documentation and targeted peer-reviewed literature to compare core regulatory functions across jurisdictions, including approval pathways and evidentiary expectations, inspection and good manufacturing practice (GMP) oversight, transparency practices, and pharmacovigilance and risk-management approaches. Across regions, we observe increasing convergence in scientific expectations through initiatives such as the International Council for Harmonisation (ICH) and reliance and work-sharing models, alongside persistent differences in legal mandates, resourcing, timelines, and data requirements. These differences are most consequential for complex products (e.g., advanced therapies) and in crisis settings, where emergency or conditional authorizations amplify the need for strong lifecycle monitoring, real-world evidence governance, and cross-border communication. We conclude by outlining opportunities to strengthen regulatory resilience and equity through fit-for-purpose harmonization, investment in enabling infrastructure, and future work on interoperable data systems, signal detection, and coordinated post-marketing evaluation.
- Open Access
- 11 February 2026
- Published by MDPI AG in Preprints.org
Global Pharmaceutical Regulation: Comparative Frameworks and Operations
Pharmaceutical regulation and healthcare governmental agencies are central to protecting public health by governing clinical trials, market authorization, and post-market safety monitoring of medicinal products worldwide. Although substantial literature describes major established systems, particularly the United States Food and Drug Administration (FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and the European Union regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analysis that integrate both established and emerging regulatory authorities remain limited. This review examines the core functions of regulatory affairs across the product life cycle and compares key features of global regulatory frameworks, including approval pathways, evidentiary expectations, data transparency, and pharmacovigilance approaches. It emphasizes the need for systems thinking to balance innovation with safety, efficacy, and quality, while anticipating unintended consequences of new therapies. This evaluation also highlights how region‑specific constraints and enabling infrastructures, such as national drug‑utilization registries in parts of Europe, can shape regulatory decision‑making and post‑market evaluation. Finally, this paper discusses opportunities for stronger international alliances and greater harmonization to improve efficiency, support timely patient access to essential therapies, strengthen risk management, and reinforce global health security in an increasingly interconnected healthcare environment.
- 11 February 2026
- Published by MDPI AG in Preprints.org
Open AccessGlobal Pharmaceutical Regulation: Comparative Frameworks and Operations
Pharmaceutical regulation and healthcare governmental agencies are central to protecting public health by governing clinical trials, market authorization, and post-market safety monitoring of medicinal products worldwide. Although substantial literature describes major established systems, particularly the United States Food and Drug Administration (FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and the European Union regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analysis that integrate both established and emerging regulatory authorities remain limited. This review examines the core functions of regulatory affairs across the product life cycle and compares key features of global regulatory frameworks, including approval pathways, evidentiary expectations, data transparency, and pharmacovigilance approaches. It emphasizes the need for systems thinking to balance innovation with safety, efficacy, and quality, while anticipating unintended consequences of new therapies. This evaluation also highlights how region‑specific constraints and enabling infrastructures, such as national drug‑utilization registries in parts of Europe, can shape regulatory decision‑making and post‑market evaluation. Finally, this paper discusses opportunities for stronger international alliances and greater harmonization to improve efficiency, support timely patient access to essential therapies, strengthen risk management, and reinforce global health security in an increasingly interconnected healthcare environment.